“A big, headline-grabbing company is not always your best bet, assuming you’re a shrewd investor seeking to maximize your profits,” advises the author of today’s article – and this may be especially true when it comes to biotech stocks. What two “size benefits” do smaller companies have – and why does the “size factor” work? CLICK HERE.
“I think this is the ground floor of a market that could be worth more than $29 billion by the end of the decade,” declares the author of today’s article of the “New Biotech” sector he discusses: psychedelics. For more on the potential profit opportunities associated with the “Shroom Boom” – especially in light of recent news regarding an important, successful FDA…
The trader behind the strategy highlighted in today’s article is typically not a day trader, but in what he acknowledges are “definitely not normal times” for the stock market right now, he no longer holds positions overnight, arguing that has become too risky. Instead, he has been employing a strategy that has proven to be profitable – even when he’s…